WO2003008966A1 - Agents de prevention/de traitement du cancer et agents de diagnostic - Google Patents

Agents de prevention/de traitement du cancer et agents de diagnostic Download PDF

Info

Publication number
WO2003008966A1
WO2003008966A1 PCT/JP2002/007204 JP0207204W WO03008966A1 WO 2003008966 A1 WO2003008966 A1 WO 2003008966A1 JP 0207204 W JP0207204 W JP 0207204W WO 03008966 A1 WO03008966 A1 WO 03008966A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
preventives
remedies
metastasis
diagnostics
Prior art date
Application number
PCT/JP2002/007204
Other languages
English (en)
Japanese (ja)
Inventor
Yuichi Hikichi
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of WO2003008966A1 publication Critical patent/WO2003008966A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention a pour objet la mise au point de médicaments anticancéreux ciblant des molécules exprimées spécifiquement dans des cellules cancéreuses, et de médicaments anti-métastases. A cet effet, l'invention fait intervenir un composé pouvant être utilisé dans des agents de prévention/de traitement du cancer, des inhibiteurs de métastases ou des agents de prévention des métastases. L'utilisation de l'ADN employé dans ce cas rend possible le diagnostic ou l'analyse du cancer et de ses métastases.
PCT/JP2002/007204 2001-07-17 2002-07-16 Agents de prevention/de traitement du cancer et agents de diagnostic WO2003008966A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-217186 2001-07-17
JP2001217186 2001-07-17

Publications (1)

Publication Number Publication Date
WO2003008966A1 true WO2003008966A1 (fr) 2003-01-30

Family

ID=19051559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007204 WO2003008966A1 (fr) 2001-07-17 2002-07-16 Agents de prevention/de traitement du cancer et agents de diagnostic

Country Status (1)

Country Link
WO (1) WO2003008966A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054322A1 (fr) * 1997-05-29 1998-12-03 Board Of Regents, The University Of Texas System Compositions de osf2/cbfa1 et procedes d'utilisation
JPH1118787A (ja) * 1997-04-23 1999-01-26 Sumitomo Pharmaceut Co Ltd 骨形成促進剤の新規なスクリーニング方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1118787A (ja) * 1997-04-23 1999-01-26 Sumitomo Pharmaceut Co Ltd 骨形成促進剤の新規なスクリーニング方法
WO1998054322A1 (fr) * 1997-05-29 1998-12-03 Board Of Regents, The University Of Texas System Compositions de osf2/cbfa1 et procedes d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAGARAJAN SELVAMURUGAN: "Constitutive expression and regulation of collagenase-3 in human breast cancer cells", MOLECULAR CELL BIOLOGY RESEARCH COMMUNICATIONS, vol. 3, 2000, pages 218 - 223, XP002957630 *
XIAO Z.S.: "Genomic structure and isoform expression of the mouse, rat and human Cbfa1/Osf2 transcription factor", GENE, vol. 214, 3 July 1998 (1998-07-03), pages 187 - 197, XP004149217 *

Similar Documents

Publication Publication Date Title
WO2005014035A3 (fr) Utilisation de galactose oxydase pour la conjugaison chimique selective de molecules d'extraction a des proteines d'interet therapeutique
ATE444984T1 (de) Hydrolysestabile maleimidendgruppen-enthaltende polymere
IL212752A0 (en) An molecule directed against the ??-secretase cleavage site of amyloid precursor protein, and uses thereof
WO2005051305A3 (fr) Apport ameliore d'un medicament
WO2008008797A3 (fr) Chélate luminescent de 1-hydroxy-2-pyridinone et de lanthanides
WO2006085987A3 (fr) Arn interference dans des cellules epitheliales respiratoires
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2005030984A3 (fr) Procede de synthese de petites quantites d'acides nucleiques
WO2003072014A3 (fr) Compositions minicellulaires et methodes associees
WO2002050122A3 (fr) Nouveaux moyens destines au diagnostic et la therapie de ctcl
WO2007001412A3 (fr) Compositions et procedes pour les utilisations et la production a grande echelle de nano-oignons de carbone
AU2002317172A1 (en) Tools for the diagnosis, molecular definition and development of treatment of chronic inflammatory joint diseases
WO2008078109A3 (fr) Médicament
WO2004105773A3 (fr) Utilisation de s1p
NO20032244D0 (no) Brönnbehandlingsprosess
WO2003102185A3 (fr) Procedes et compositions pour traiter une neoplasie associee aux molecules d'acides nucleiques de a1 et a2 de hnrnp
AU2002346676A1 (en) Traction fluids
AU2002241996A1 (en) Fluid and bioaerosol management
WO2003008966A1 (fr) Agents de prevention/de traitement du cancer et agents de diagnostic
WO2004073686A3 (fr) Solutions de medicaments dans du menthol
WO2002079495A3 (fr) Applications genomiques destinees a des oligonucleotides modifies
WO2005023422A3 (fr) Preparation et utilisation de liquides ioniques comprenant des anions thiocyanato
WO2004041196A3 (fr) Procedes et compositions pour le diagnostic du cancer du poumon neuroendocrinien
WO2004067569A8 (fr) Molecules de liaison humaines d'internalisation dirigees contre cd72
WO2007030802A3 (fr) Agents de contraste cibles et leurs procedes de ciblage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP